Partners in Crime: NGF and BDNF in Visceral Dysfunction

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Coelho, A (Author) Other; Oliveira, R (Author) Other; Antunes Lopes, T (Author) FMUP; Cruz C.D. (Author) FMUP

Journal

Title: Current Neuropharmacology

Vol. 17

Pages: 1021-1038

ISSN: 1570-159X

Publisher: Bentham Science

Indexing

ISI Web of Knowledge - 27 Citations

Scopus - 30 Citations

Other information

Authenticus ID: P-00R-5ZJ

DOI: 10.2174/1570159x17666190617095844

Abstract (EN): Neurotrophins (NTs), particularly Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), have attracted increasing attention in the context of visceral function for some years. Here, we examined the current literature and presented a thorough review of the subject. After initial studies linking of NGF to cystitis, it is now well-established that this neurotrophin (NT) is a key modulator of bladder pathologies, including Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS. NGF is upregulated in bladder tissue and its blockade results in major improvements on urodynamic parameters and pain. Further studies expanded showed that NGF is also an intervenient in other visceral dysfunctions such as endometriosis and Irritable Bowel Syndrome (IBS). More recently, BDNF was also shown to play an important role in the same visceral dysfunctions, suggesting that both NTs are determinant factors in visceral pathophysiological mechanisms. Manipulation of NGF and BDNF improves visceral function and reduce pain, suggesting that clinical modulation of these NTs may be important; however, much is still to be investigated before this step is taken. Another active area of research is centered on urinary NGF and BDNF. Several studies show that both NTs can be found in the urine of patients with visceral dysfunction in much higher concentration than in healthy individuals, suggesting that they could be used as potential biomarkers. However, there are still technical difficulties to be overcome, including the lack of a large multicentre placebo-controlled studies to prove the relevance of urinary NTs as clinical biomarkers.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 18